DOCSLIB.ORG

Download The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download The Application of Stable Isotope Labeled Diphenhydramine to Study the Pharmacokinetics and Metabolism of Diphenhydramine in Pregnant, Non- Pregnant, and Fetal Sheep. By George Roger Tonn B.Sc. (Pharm.), University of British Columbia, Vancouver, Canada, 1988. M.Sc. (Pharm.), University of British Columbia, Vancouver, Canada, 1990. A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in THE FACULTY OF GRADUATE STUDIES (Faculty of Pharmaceutical Sciences) (Division of Biopharmaceutics and Pharmaceutics) We accept this thesis as conforming to the standard required THE UNIVERSITY OF BRITISH COLUMBIA February, 1995 © George Roger Tonn, 1995 advanced In presenting this thesis in partial fulfilment of the requirements for an Library shall make it degree at the University of British Columbia, I agree that the that permission for extensive freely available for reference and study. I further agree copying of this thesis for scholarly purposes may be granted by the head of my department or by his or her representatives. it is understood that copying or publication of this thesis for financial gain shall not be allowed without my written permission. Department of Pharmaceutical Sciences The University of British Columbia Vancouver, Canada 2 7—02-95 Date DE-6 (2188) 11 II. Abstract Diphenhydramine (DPHM), an antihistamine, has been used in pregnant women; however, information regarding its disposition in human pregnancy is lacking. Recently, detailed pharmacokinetic studies in pregnant sheep have demonstrated that DPHM readily crosses the ovine placenta, and is eliminated from the fetus by placental and non-placental pathways. The purpose of this study is to investigate the components of the fetal non-placental elimination (i.e., fetal renal and hepatic), and to compare these to the estimates obtained from adult sheep. Since stable isotope techniques were to be employed, synthesis of stable isotope labeled DPHM (i.e., {2H10]DPMA) was [2H10]DPHM) and its major metabolite diphenylmethoxyacetic acid (i.e., required. Next, gas chromatographic - mass spectrometric methods were developed to [2H10]DPHM, or DPMA and [2H10]DPMA. The simultaneously measure either DPHM and current study demonstrates that the measured fetal renal clearance of DPHM contributes only —2% to the observed fetal non-placental clearance. Overall, the total non-placental clearance of DPHM measured by direct methods (i.e., pulmonary [Yoo, 1989] and renal) can account for 10% of the non-placental clearance. Unlike adult sheep, where hepatic extraction of DPHM was —93%, no significant extraction of DPHM by the fetal liver following umbilical venous administration was observed. Therefore, fetal hepatic elimination is not likely to account for the remainder of the fetal non-placental clearance. However, fetal hepatic in vitro metabolism of DPHM (to form N-demethyl DPHM and DPMA) suggests that the fetal liver is capable of DPHM biotransformation. Thus, the liver and possibly other organs may contribute at least a portion of the fetal non-placental clearance via DPHM biotransformation. It appears that only a small fraction of the fetal non-placental clearance of DPHM can be accounted for by fetal renal 111 and pulmonary clearances. While the low renal clearance of intact DPHM is similar both in fetus and mother, large differences in the hepatic uptake andJor metabolism of DPHM were observed between mother and fetus. This suggests that the pathways for the non-placental elimination of DPHM differ in mother and fetus. Despite the advances made in this study, the components of the fetal non-placental clearance remains largely unknown, and requires further study. iv IV. Table of Contents II. Short Abstract jj ifi. Table of Contents iv IV. List of Tables ix V. List of Figures xii VI. List of Abbreviations xvi VII. Acknowledgments xxii 1. INTRODUCTION 1 1.1. General Introduction 1 1.2. Pharmacology of DPHM 2 1.3. Toxicology of DPHM 3 1.4. Clinical Applications of DPHM 4 1.5. Therapeutic Applications of Antihistamines In Pregnancy 4 1.6. Analysis Methods for DPHM 5 1.7. Pharmacokinetics of DPHM 6 1.7.1. Absorption of DPHM 6 1.7.2. Distribution of DPHM 7 1.7.3. Metabolism of DPHM 7 1.7.4. Excretion of DPHM and its Metabolites 9 1.8. DPHM Disposition in Pregnancy 10 1.8.1. Disposition and Fetal Effects of DPHM in Pregnant Sheep 11 1.9. Stable Isotopes 14 1.10. Rationale and Objectives 16 1.11. Hypothesis and Specific Aims 17 2. EXPERIMENTAL 20 2.1. Materials 20 2.1.1. Preparation of Stock Solutions and Buffers 22 2.2. Equipment and Instrumentation 24 2.2.1. Gas Chromatography with Nitrogen Phosphorus Specific Detection 24 2.2.2. Gas Chromatography with Mass Spectrometry 25 2.2.3. Gas Chromatography/High Performance Liquid Chromatography - 25 Mass Spectrometry 2.2.4. Spectrophotometer 25 2.2.5. Physiological Monitoring 25 2.2.6. General Experimental Equipment 26 2.3. Chemical Synthesis of Standards and Metabolites of DPHM 27 [2Hiojbenzhydrol 27 2.3.1. Synthesis of [2H10]DPHM HC1 29 2.3.2. Synthesis of [2H10]DPHM 31 2.3.2.1. Characterization of V 2.3.3. Synthesis of N-demethyl DPHM HC1 and N,N-didemethyl DPHM HC1 31 2.3.3.1. Characterization of N-demethyl DPHM and N,N-didemethyl DPHM 31 {2H10]DPMA 2.3.4. Synthesis of DPMA and 32 [2H IO]DPMA 2.3.4.1. Characterization of DPMA and 33 2.3.5. Purity Assessment of Synthesized Standards. 35 2.4. Analytical Method Development 37 Development Analysis Method [2H10]DPHM 2.4.1. of an for DPHM and 37 2.4.1.1. Optimization of Mass Spectrometer Parameters 37 2.4.1.2. Optimization of Gas Chromatographic Parameters 37 2.4.1.3. Optimization of Extraction Procedure 38 2.4.1.4. Gas Chromatography - Mass Spectrometer Operating Conditions 38 [2H10JDPHM Extraction Procedure 2.4.1.5. DPHM and 39 2.4.1.6. Preparation of a Calibration Curve 40 Calculation of Extraction Recoveries [2H10]DPHM 41 2.4.1.7. of DPHM and 2.4.1.8. Sample Stability Assessment 41 2.4.1.9. Method Validation 42 Development of an [2H10]DPMA 43 2.4.2. Analysis Method for DPMA and 2.4.2.1. Optimization of Mass Spectrometer Conditions 43 2.4.2.2. Optimization of Gas Chromatograph Conditions 43 2.4.2.3. Optimization of Extraction 44 2.4.2.4. Optimization of Derivatization 44 2.4.2.5. Gas Chromatograph - Mass Spectrometer Operating Conditions 45 [2H10]DPMA Extraction Procedure 46 2.4.2.6. DPMA and 2.4.2.7. Preparation of a Calibration Curve 47 [2H10]DPMA 47 2.4.2.8. Calculation of Extraction Recovery of DPMA and 2.4.2.9. Sample Stability Assessment 47 2.4.2.10. Method Validation 48 2.5. Standard Procedures for Animal Experiments 48 2.5.1. Animal Handling 48 2.5.2. Surgical Preparation for Chronic Experimentation 49 2.5.2.1. Non-pregnant Sheep - Surgical Preparation 49 2.5.2.2. Pregnant Sheep - Surgical Preparation 51 2.5.3. Chronic Monitoring of Animals 55 2.5.3.1. Amniotic, Tracheal, and Vascular Pressures, Heart rate, Blood Flow, 55 ECoG and EOG. 2.5.3.2. Fetal Urine Measurements 55 2.5.3.3. Blood Gas Analysis 56 2.5.3.4. Glucose and Lactate measurements 56 2.5.4. Dosage Preparation 57 2.6. Experimental Protocols 57 2.6.1. Adult Non-Pregnant Studies 57 2.6.2. Adult Isotope Effect Studies 57 2.6.3. Fetal Isotope Effect Studies 58 2.6.3.1. FetalBolus 58 2.6.3.2. Fetallnfusion 58 vi 2.6.4. Adult First-Pass Metabolism 59 2.6.4.1. Adult First-Pass Metabolism During Normoxia 59 2.6.4.2. Adult First-Pass Metabolism During Mild Hypoxemia 60 2.6.5. Fetal Hepatic First-Pass Metabolism 60 2.6.5.1. Fetal Umbilical Venous Bolus 60 2.6.5.2. Fetal Umbilical Venous Infusion 61 2.6.6. Paired Fetal/Maternal Infusion 62 2.6.7. Sample Handling 63 2.7. In Vitro Experiments 63 2.7.1. DPHM Red Blood Cell Uptake 63 2.7.2. Adult and Fetal Hepatic Microsomal Metabolism Experiments 64 2.7.2.1. Preparation of Adult and Fetal Hepatic Microsomes 64 2.7.2.2. Protein Concentration and Cytochrome P450 Measurements 66 2.7.2.3. DPHM and N-demethyl DPHM Quantitation 66 2.7.2.4. Fetal and Adult Hepatic Microsomal Incubations 67 2.7.3. Plasma Protein Binding of DPMA 67 2.8. Data Analysis 69 2.8.1. Data Reduction 69 2.8.2. Calculation of In Utero Fetal Weight 69 2.8.3. Pharmacokinetic Data Analysis 70 2.8.4. Statistical Analysis 79 3. RESULTS 81 3.1. Development of Analytical Methodology 81 3.1.1. Capillary Gas Chromatographic-Mass Spectrometric Analysis of DPHM 81 [2H10]DPHM and 3.1.1.1. Optimization of Mass Spectrometer and Gas Chromatograph 81 Optimization of the Extraction Procedure for the DPHM [2H10IDPHM 85 3.1.1.2. and Analysis Method [2H10]DPHM Assay 3.1.1.3. Calibration Curve for the DPHM and 90 {2H10]DPHM 3.1.1.4. Extraction Recoveries of DPHM and 91 [2H10]DPHM 3.1.1.5. Sample Stability Assessment of DPHM 91 [2H10]DPHM Gas Chromatographic - 3.1.1.6. Validation of DPHM and Mass 93 Spectrometric Analysis Method Capillary Gas Chromatographic - Mass Spectrometric Analysis of DPMA 96 3.1.2. [2H10IDPMA and 3.1.2.1. Optimization of Mass Spectrometer and Gas Chromatography 96 3.1.2.2. Optimization of Extraction and Derivatization Procedures for DPMA 100 and [2H10JDPMA [2H10]DPMA 102 3.1.2.3. Calibration Curve for DPMA and {2H10]DPMA 3.1.2.4.
Load more

Recommended publications
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Questions in the Chemical Enzymology of MAO
    Review Questions in the Chemical Enzymology of MAO Rona R. Ramsay 1,* and Alen Albreht 2 1 Biomedical Sciences Research Complex, School of Biology, University of St Andrews, St Andrews KY16 9ST, UK 2 Laboratory for Food Chemistry, Department of Analytical Chemistry, National Institute of Chemistry, Hajdrihova 19, SI-1000 Ljubljana, Slovenia; [email protected] * Correspondence: [email protected]; Tel.: +44-(0)-1334-474740 Abstract: We have structure, a wealth of kinetic data, thousands of chemical ligands and clinical information for the effects of a range of drugs on monoamine oxidase activity in vivo. We have comparative information from various species and mutations on kinetics and effects of inhibition. Nevertheless, there are what seem like simple questions still to be answered. This article presents a brief summary of existing experimental evidence the background and poses questions that remain intriguing for chemists and biochemists researching the chemical enzymology of and drug design for monoamine oxidases (FAD-containing EC 4.1.3.4). Keywords: chemical mechanism; kinetic mechanism; oxidation; protein flexibility; cysteine modifica- tion; reversible/irreversible inhibition; molecular dynamics; simulation 1. Introduction Monoamine oxidase (E.C. 1.4.3.4) enzymes MAO A and MAO B are FAD-containing Citation: Ramsay, R.R.; Albreht, A. proteins located on the outer face of the mitochondrial inner membrane, retained there Questions in the Chemical Enzymology of MAO. Chemistry 2021, by hydrophobic interactions and a transmembrane helix. The redox co-factor (FAD) is 3, 959–978. https://doi.org/10.3390/ covalently attached to a cysteine and buried deep inside the protein [1].
    [Show full text]
  • Azilect, INN-Rasagiline
    SCIENTIFIC DISCUSSION 1. Introduction AZILECT is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations. Rasagiline is administered orally, at a dose of 1 mg once daily with or without levodopa. Parkinson’s disease is a common neurodegenerative disorder typified by loss of dopaminergic neurones from the basal ganglia, and by a characteristic clinical syndrome with cardinal physical signs of resting tremor, bradikinesia and rigidity. The main treatment aims at alleviating symptoms through a balance of anti-cholinergic and dopaminergic drugs. Parkinson’s disease (PD) treatment is complex due to the progressive nature of the disease, and the array of motor and non-motor features combined with early and late side effects associated with therapeutic interventions. Rasagiline is a chemical inhibitor of the enzyme monoamine oxidase (MAO) type B which has a major role in the inactivation of biogenic and diet-derived amines in the central nervous system. MAO has two isozymes (types A and B) and type B is responsible for metabolising dopamine in the central nervous system; as dopamine deficiency is the main contributing factor to the clinical manifestations of Parkinson’s disease, inhibition of MAO-B should tend to restore dopamine levels towards normal values and this improve the condition. Rasagiline was developed for the symptomatic treatment of Parkinson’s disease both as monotherapy in early disease and as adjunct therapy to levodopa + aminoacids decarboxylase inhibitor (LD + ADI) in patients with motor fluctuations. 2. Quality Introduction Drug Substance • Composition AZILECT contains rasagiline mesylate as the active substance.
    [Show full text]
  • Evidence That Formulations of the Selective MAO-B Inhibitor, Selegiline, Which Bypass First-Pass Metabolism, Also Inhibit MAO-A in the Human Brain
    Neuropsychopharmacology (2015) 40, 650–657 OPEN & 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain Joanna S Fowler*,1, Jean Logan2, Nora D Volkow3,4, Elena Shumay4, Fred McCall-Perez5, Millard Jayne4, Gene-Jack Wang4, David L Alexoff1, Karen Apelskog-Torres4, Barbara Hubbard1, Pauline Carter1, 1 6 7 4 1 1 4 Payton King , Stanley Fahn , Michelle Gilmor , Frank Telang , Colleen Shea , Youwen Xu and Lisa Muench 1Biological, Environmental and Climate Sciences Department, Brookhaven National Laboratory, Upton, NY, USA; 2New York University Langone Medical Center, Department of Radiology, New York, NY, USA; 3National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, 4 5 USA; National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA; Targeted Medical Pharma Inc, 6 7 Los Angeles, CA, USA; Department of Neurology, Columbia University Medical Center, New York, NY, USA; Novartis Pharmaceuticals, East Hanover, NJ, USA Selegiline (L-deprenyl) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10 mg/day oral) that is used in the treatment of Parkinson’s disease. However, controlled studies have demonstrated antidepressant activity for high doses of oral selegiline and for transdermal selegiline suggesting that when plasma levels of selegiline are elevated, brain MAO-A might also be inhibited. Zydis selegiline (Zelapar) is an orally disintegrating formulation of selegiline, which is absorbed through the buccal mucosa producing higher plasma levels of selegiline and reduced amphetamine metabolites compared with equal doses of conventional selegiline.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Potent Inhibition of Monoamine Oxidase B by a Piloquinone from Marine-Derived Streptomyces Sp. CNQ-027
    J. Microbiol. Biotechnol. (2017), 27(4), 785–790 https://doi.org/10.4014/jmb.1612.12025 Research Article Review jmb Potent Inhibition of Monoamine Oxidase B by a Piloquinone from Marine-Derived Streptomyces sp. CNQ-027 Hyun Woo Lee1, Hansol Choi2, Sang-Jip Nam2, William Fenical3, and Hoon Kim1* 1Department of Pharmacy and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea 2Department of Chemistry and Nano Science, Ewha Womans University, Seoul 03760, Republic of Korea 3Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, La Jolla, CA 92093-0204, USA Received: December 19, 2016 Revised: December 27, 2016 Two piloquinone derivatives isolated from Streptomyces sp. CNQ-027 were tested for the Accepted: January 4, 2017 inhibitory activities of two isoforms of monoamine oxidase (MAO), which catalyzes monoamine neurotransmitters. The piloquinone 4,7-dihydroxy-3-methyl-2-(4-methyl-1- oxopentyl)-6H-dibenzo[b,d]pyran-6-one (1) was found to be a highly potent inhibitor of First published online human MAO-B, with an IC50 value of 1.21 µM; in addition, it was found to be highly effective January 9, 2017 against MAO-A, with an IC50 value of 6.47 µM. Compound 1 was selective, but not extremely *Corresponding author so, for MAO-B compared with MAO-A, with a selectivity index value of 5.35. Compound 1,8- Phone: +82-61-750-3751; dihydroxy-2-methyl-3-(4-methyl-1-oxopentyl)-9,10-phenanthrenedione (2) was moderately Fax: +82-61-750-3708; effective for the inhibition of MAO-B (IC = 14.50 µM) but not for MAO-A (IC > 80 µM).
    [Show full text]
  • Some Pharmacological Properties of Trimethoxy Analogs of Pheniramine, Tripelennamine, and Diphenhydramine
    University of Rhode Island DigitalCommons@URI Open Access Master's Theses 1966 Some Pharmacological Properties of Trimethoxy Analogs of Pheniramine, Tripelennamine, and Diphenhydramine Ronald Otto Langner University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/theses Recommended Citation Langner, Ronald Otto, "Some Pharmacological Properties of Trimethoxy Analogs of Pheniramine, Tripelennamine, and Diphenhydramine" (1966). Open Access Master's Theses. Paper 200. https://digitalcommons.uri.edu/theses/200 This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. SOME PHARMACOLOGICAL PRDPERTIES OF TRIMETHOXY ANALOGS OF PHENIRAMINE,_ TRIPELENNAMINE, AND DIPHENHYDRAMINE BY RONALD OT'ID LANGNER A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FDR THE DEGREE OF MASTER OF SCIENCE IN PHARMACOLOGY UNIVERSITY OF RHODE ISLAND 1966 ABSTRACT Trimethoxy analogs of tripelennamine, diphenhydramine, and pheniramine were studied to determine the influences of the tri­ methoxy group on the pharmacological activity of known antihista­ mines. In this investigation, the ability of the parent compounds and their analogs to antagonize the histamine-induced contractions of guinea pig ilia were studied as well as their effects on the systolic blood pressure of male albino rats and on the central nervous system of mice as measured by the actophotometer. 'lhe trimethoxy analogs were comparatively weak competitive antagonists of histamine with the exception of N,N,-Diethyl-N'­ (2-pyridyl)-N'-(3,4,S-trimethoxybenzyl) ethylenediamine Dicyclamate (De-TMPBZ) and N,N,-Diethyl-N'-(2-pyridyl)-N'-(3,4,5-trimethoxy­ benzyl) ethylenediamine Disuccinate (TMPBZ) which were weak non­ competitive histamine antagonists.
    [Show full text]
  • Pharmacological Aspects of the Neuroprotective Effects Of
    Journal of Neural Transmission https://doi.org/10.1007/s00702-018-1853-9 NEUROLOGY AND PRECLINICAL NEUROLOGICAL STUDIES - REVIEW ARTICLE Pharmacological aspects of the neuroprotective efects of irreversible MAO‑B inhibitors, selegiline and rasagiline, in Parkinson’s disease Éva Szökő1 · Tamás Tábi1 · Peter Riederer2 · László Vécsei3,4 · Kálmán Magyar1 Received: 4 January 2018 / Accepted: 31 January 2018 © Springer-Verlag GmbH Austria, part of Springer Nature 2018 Abstract The era of MAO-B inhibitors dates back more than 50 years. It began with Kálmán Magyar’s outstanding discovery of the selective inhibitor, selegiline. This compound is still regarded as the gold standard of MAO-B inhibition, although newer drugs have also been introduced to the feld. It was revealed early on that selective, even irreversible inhibition of MAO-B is free from the severe side efect of the non-selective MAO inhibitors, the potentiation of tyramine, resulting in the so-called ‘cheese efect’. Since MAO-B is involved mainly in the degradation of dopamine, the inhibitors lack any antidepressant efect; however, they became frst-line medications for the therapy of Parkinson’s disease based on their dopamine-sparing activity. Extensive studies with selegiline indicated its complex pharmacological activity profle with MAO-B-independent mechanisms involved. Some of these benefcial efects, such as neuroprotective and antiapoptotic properties, were connected to its propargylamine structure. The second MAO-B inhibitor approved for the treatment of Parkinson’s disease, rasagiline also possesses this structural element and shows similar pharmacological characteristics. The preclinical studies performed with selegiline and rasagiline are summarized in this review. Keywords MAO-B inhibition · Selegiline · Rasagiline · Neuroprotection Introduction inhibitor in the 1960s (Knoll et al.
    [Show full text]
  • Application Number
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207145Orig1s000 PHARMACOLOGY REVIEW(S) Tertiary Pharmacology Review By: Paul C. Brown, Ph.D., ODE Associate Director for Pharmacology and Toxicology, OND IO NDA: 207145 Submission date: 5/29/2014 Drug: Safinamide Applicant: Newron Pharmaceuticals Indication: adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes Reviewing Division: Division of Neurology Products Discussion: The primary reviewer and supervisor found the nonclinical information adequate to support the approval of safinamide for the indication listed above. Safinamide is an inhibitor of monoamine oxidase B. Although the exact mechanism by which safinamide exerts it therapeutic effect is not known, increased dopaminergic activity in the brain induced by inhibition of monoamine oxidase B is thought to be beneficial in Parkinson’s disease. The Established Pharmacologic Class of Monoamine Oxidase Type B Inhibitor is appropriate for safinamide. The carcinogenicity of safinamide was assessed in 2-year rat and mouse studies. These studies were found to be acceptable by the executive carcinogenicity assessment committee and the committee concluded that there were no drug- related neoplasms in either species. Retinal toxicity and cataracts were observed in rats treated with safinamide. These effects occurred at exposures below those achieved in humans at the maximum recommended dose. The relevance to humans is unknown but cannot be excluded. Proposed labeling includes warning about this possible toxicity. Safinamide alone and in combination with levodopa and carbidopa produced adverse developmental effects in animals at doses similar to those used in humans. Proposed labeling includes description of these findings. Conclusions: I agree that this NDA can be approved from a pharm/tox perspective for the indication listed above.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Monoamine Oxidase Inhibition Causes a Long-Term Prolongation of the Dopamine-Induced Responses in Rat Midbrain Dopaminergic Cells
    The Journal of Neuroscience, April 1, 1997, 17(7):2267–2272 Monoamine Oxidase Inhibition Causes a Long-Term Prolongation of the Dopamine-Induced Responses in Rat Midbrain Dopaminergic Cells Nicola B. Mercuri, Mariangela Scarponi, Antonello Bonci, Antonio Siniscalchi, and Giorgio Bernardi Clinica Neurologica, Dipartimento Sanita´ Pubblica, Universita´ di Roma Tor Vergata and Istituto Ricerca e Cura a Carattere Scientifico Ospedale Santa Lucia, Roma, Italy The way monoamine oxidase (MAO) modulates the depression over, the effects of DA were not largely prolonged during the of the firing rate and the hyperpolarization of the membrane simultaneous inhibition of MAO and the DA reuptake system. caused by dopamine (DA) on rat midbrain dopaminergic cells Interestingly, the actions of amphetamine were not clearly aug- was investigated by means of intracellular recordings in vitro. mented by MAO inhibition. The cellular responses to DA, attributable to the activation of From the present data it is concluded that the termination of somatodendritic D2/3 autoreceptors, were prolonged and did DA action in the brain is controlled mainly by MAO enzymes. not completely wash out after pharmacological blockade of This long-term prolongation of the dopaminergic responses both types (A and B) of MAO. On the contrary, depression of the suggests a substitutive therapeutic approach that uses MAO firing rate and membrane hyperpolarization induced by quinpi- inhibitors and DA precursors in DA-deficient disorders in which role (a direct D2 receptor agonist) were not affected by MAO continuous stimulation of the dopaminergic receptors is inhibition. Furthermore, although the inhibition of DA reuptake preferable. by cocaine and nomifensine caused a short-term prolongation of DA responses, the combined inhibition of MAO A and B Key words: pargyline; cocaine; nomifensine; intracellular re- enzymes caused a long-term prolongation of DA effects.
    [Show full text]
  • ANTIHISTAMINES Antihistamines Need to Be Stopped 7 Days Prior to Allergy Testing
    ANTIHISTAMINES Antihistamines need to be stopped 7 days prior to allergy testing Actifed Cetirizine Extendryl Rutuss Advil Allergy Chlorphenirmine Fexofenadine Ryna Advil PM Clortrimeton Hydroxyzine Rynatan Alavert Clarinex Hyzine Ryneze Allegra Claritin Lodrane Semprex Allerhist Clemastine Loratadine Singlet Allertan Cogentin Nyquil Sominex Allerx Comtrex Omnaris nasal spray Astelin nasal spray Contac Optivar eye drops Tandur Astepro nasal spray Coricidin Pataday Travist Atarax Cyproheptadine Patanase nasal spray Temaril Atrohist Deconamine Patanol eye drops Theraflu BC Cold Dimetapp PediaCare Triaminic Benadryl Diphenhydramine Pediatan Trinalin Bentyl Dramamine Periactin Tylenol (any but plain) Benztropin Drixoral Polyhistine Unisom Biohist Durahist Pyribenzamine Vicks Bonine Duratan Rescon Vistacot Bromfed Duravent Restall Vistaril IM Brompheniramine Dytan Robitussin Xyzal Carbinoxamine Excedrin PM Rondec Zyrtec ANTI-INFLAMMATORY Anti-inflammatory medications must be stopped 7 days prior to allergy testing Aspirin Celebrex Motrin Aleve Naprosyn (Naproxen) Flexeril Advil Excedrin (PM & Cold/Sinus) Ibuprofen Alka-Seltzer Prednisone Vioxx Meloxicam cold medications BETA BLOCKERS Beta blocker drugs need to be stopped 7 days prior to allergy testing. DO NOT STOP WITHOUT PRESCRIBING PROVIDERS AUTHORIZATION! ORAL COMBINATION PRODUCTS Brand Name Generic Name Brand Name Generic Name Apo-Metoprolol metoprolol Cobetaloc metroprolol/HCTZ Apo-Propranolol propranolol Corzide Nadolol Betaloc metoprolol Inderide propranolol/HCTZ Betapace/AF sotalol
    [Show full text]